Current Colorectal Cancer Reports

, Volume 10, Issue 4, pp 411–416 | Cite as

Targeting Notch Signaling in Colorectal Cancer

  • Suman Suman
  • Trinath P. Das
  • Murali K. Ankem
  • Chendil DamodaranEmail author
Molecular Biology (S Anant, Section Editor)


The activation of Notch signaling is implicated in tumorigenesis in the colon due to the induction of pro-survival signaling in colonic epithelial cells. Chemoresistance is a major obstacle for treatment and for the complete eradication of colorectal cancer (CRC); hence, the inhibition of Notch is an attractive target for CRC and several groups are working to identify small molecules or monoclonal antibodies that inhibit Notch or its downstream events; however, toxicity profiles in normal cells and organs often impede the clinical translation of these molecules. Dietary agents have gained momentum for targeting several pro-survival signaling cascades, and recent studies demonstrated that agents that inhibit Notch signaling result in growth inhibition in preclinical models of CRC. In this review, we focus on the importance of Notch as a preventive and therapeutic target for colon cancer and on the effect of WA on this signaling pathway in the context of colon cancer.


Notch-1 Chemoresistance Dietary agent Prevention Treatment Colon cancer 



This study was supported by NIH Grant 1R01CA185972-01.

Compliance with Ethics Guidelines

Conflict of Interest

Suman Suman, Trinath P. Das, Murali. K. Ankem, and Chendil Damodaran declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Miyamoto S, Rosenberg DW. Role of Notch signaling in colon homeostasis and carcinogenesis. Cancer Sci. 2011;102(11):1938–42.PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    Jemal A et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.PubMedCrossRefGoogle Scholar
  3. 3.
    Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin. 2014;64(2):104–17.PubMedCrossRefGoogle Scholar
  4. 4.
    Wu WK et al. Dysregulation and crosstalk of cellular signaling pathways in colon carcinogenesis. Crit Rev Oncol Hematol. 2013;86(3):251–77.PubMedCrossRefGoogle Scholar
  5. 5.•
    Noah TK, Shroyer NF. Notch in the intestine: regulation of homeostasis and pathogenesis. Annu Rev Physiol. 2013;75:263–88. This article describe the role of Notch in intestinal homeostasis and colorectal cancer.PubMedCrossRefGoogle Scholar
  6. 6.
    Qiao L, Wong BC. Role of Notch signaling in colorectal cancer. Carcinogenesis. 2009;30(12):1979–86.PubMedCrossRefGoogle Scholar
  7. 7.
    Barolo S, Posakony JW. Three habits of highly effective signaling pathways: principles of transcriptional control by developmental cell signaling. Genes Dev. 2002;16(10):1167–81.PubMedCrossRefGoogle Scholar
  8. 8.
    van Tetering G et al. Metalloprotease ADAM10 is required for Notch1 site 2 cleavage. J Biol Chem. 2009;284(45):31018–27.PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Meng RD et al. gamma-Secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity. Cancer Res. 2009;69(2):573–82.PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Blaumueller CM et al. Intracellular cleavage of Notch leads to a heterodimeric receptor on the plasma membrane. Cell. 1997;90(2):281–91.PubMedCrossRefGoogle Scholar
  11. 11.
    Fre S et al. Notch signals control the fate of immature progenitor cells in the intestine. Nature. 2005;435(7044):964–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Pellegrinet L et al. Dll1- and dll4-mediated notch signaling are required for homeostasis of intestinal stem cells. Gastroenterology. 2011;140(4):1230–40. e1-7.PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Radtke F, Clevers H, Riccio O. From gut homeostasis to cancer. Curr Mol Med. 2006;6(3):275–89.PubMedCrossRefGoogle Scholar
  14. 14.
    Zheng H et al. KLF4 gene expression is inhibited by the notch signaling pathway that controls goblet cell differentiation in mouse gastrointestinal tract. Am J Physiol Gastrointest Liver Physiol. 2009;296(3):G490–8.PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Riccio O et al. Loss of intestinal crypt progenitor cells owing to inactivation of both Notch1 and Notch2 is accompanied by depression of CDK inhibitors p27Kip1 and p57Kip2. EMBO Rep. 2008;9(4):377–83.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Schroder N, Gossler A. Expression of Notch pathway components in fetal and adult mouse small intestine. Gene Expr Patterns. 2002;2(3–4):247–50.PubMedCrossRefGoogle Scholar
  17. 17.
    Sander GR, Powell BC. Expression of notch receptors and ligands in the adult gut. J Histochem Cytochem. 2004;52(4):509–16.PubMedCrossRefGoogle Scholar
  18. 18.
    VanDussen KL et al. Notch signaling modulates proliferation and differentiation of intestinal crypt base columnar stem cells. Development. 2012;139(3):488–97.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Vooijs M et al. Mapping the consequence of Notch1 proteolysis in vivo with NIP-CRE. Development. 2007;134(3):535–44.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Fre S et al. Notch lineages and activity in intestinal stem cells determined by a new set of knock-in mice. PLoS One. 2011;6(10):e25785.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Kosinski C et al. Gene expression patterns of human colon tops and basal crypts and BMP antagonists as intestinal stem cell niche factors. Proc Natl Acad Sci U S A. 2007;104(39):15418–23.PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    van Es JH et al. Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature. 2005;435(7044):959–63.PubMedCrossRefGoogle Scholar
  23. 23.
    Stanger BZ et al. Direct regulation of intestinal fate by Notch. Proc Natl Acad Sci U S A. 2005;102(35):12443–8.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Fre S et al. Notch and Wnt signals cooperatively control cell proliferation and tumorigenesis in the intestine. Proc Natl Acad Sci U S A. 2009;106(15):6309–14.PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Katoh M, Katoh M. Notch signaling in gastrointestinal tract (review). Int J Oncol. 2007;30(1):247–51.PubMedGoogle Scholar
  26. 26.
    Shroyer NF et al. Intestine-specific ablation of mouse atonal homolog 1 (Math1) reveals a role in cellular homeostasis. Gastroenterology. 2007;132(7):2478–88.PubMedCrossRefGoogle Scholar
  27. 27.
    Yang Q et al. Requirement of Math1 for secretory cell lineage commitment in the mouse intestine. Science. 2001;294(5549):2155–8.PubMedCrossRefGoogle Scholar
  28. 28.
    Zheng X et al. Suppression of hath1 gene expression directly regulated by hes1 via notch signaling is associated with goblet cell depletion in ulcerative colitis. Inflamm Bowel Dis. 2011;17(11):2251–60.PubMedCrossRefGoogle Scholar
  29. 29.
    Schroeter EH, Kisslinger JA, Kopan R. Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain. Nature. 1998;393(6683):382–6.PubMedCrossRefGoogle Scholar
  30. 30.
    Yin L, Velazquez OC, Liu ZJ. Notch signaling: emerging molecular targets for cancer therapy. Biochem Pharmacol. 2010;80(5):690–701.PubMedCrossRefGoogle Scholar
  31. 31.
    Ellisen LW et al. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell. 1991;66(4):649–61.PubMedCrossRefGoogle Scholar
  32. 32.
    Pear WS et al. Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles. J Exp Med. 1996;183(5):2283–91.PubMedCrossRefGoogle Scholar
  33. 33.
    Kimura K et al. Activation of Notch signaling in tumorigenesis of experimental pancreatic cancer induced by dimethylbenzanthracene in mice. Cancer Sci. 2007;98(2):155–62.PubMedCrossRefGoogle Scholar
  34. 34.
    Wang Z et al. Down-regulation of notch-1 inhibits invasion by inactivation of nuclear factor-kappaB, vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells. Cancer Res. 2006;66(5):2778–84.PubMedCrossRefGoogle Scholar
  35. 35.
    Mao J et al. ShRNA targeting Notch1 sensitizes breast cancer stem cell to paclitaxel. Int J Biochem Cell Biol. 2013;45(6):1064–73.PubMedCrossRefGoogle Scholar
  36. 36.
    Reedijk M et al. High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res. 2005;65(18):8530–7.PubMedCrossRefGoogle Scholar
  37. 37.
    Suman S, Das TP, Damodaran C. Silencing NOTCH signaling causes growth arrest in both breast cancer stem cells and breast cancer cells. Br J Cancer. 2013;109(10):2587–96.PubMedCrossRefGoogle Scholar
  38. 38.
    Santagata S et al. JAGGED1 expression is associated with prostate cancer metastasis and recurrence. Cancer Res. 2004;64(19):6854–7.PubMedCrossRefGoogle Scholar
  39. 39.
    Marignol L. Targeting notch in prostate cancer-combination is the key. Nat Rev Urol. 2014;11(7):419.PubMedCrossRefGoogle Scholar
  40. 40.
    Kwon OJ et al. Increased Notch signalling inhibits anoikis and stimulates proliferation of prostate luminal epithelial cells. Nat Commun. 2014;5:4416.PubMedGoogle Scholar
  41. 41.
    Gao J et al. Expression of Jagged1 and its association with hepatitis B virus X protein in hepatocellular carcinoma. Biochem Biophys Res Commun. 2007;356(2):341–7.PubMedCrossRefGoogle Scholar
  42. 42.
    Tripathi R et al. Clinical impact of de-regulated Notch-1 and Notch-3 in the development and progression of HPV-associated different histological subtypes of precancerous and cancerous lesions of human uterine cervix. PLoS One. 2014;9(6):e98642.PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Ramdass B et al. Coexpression of Notch1 and NF-kappaB signaling pathway components in human cervical cancer progression. Gynecol Oncol. 2007;104(2):352–61.PubMedCrossRefGoogle Scholar
  44. 44.
    Curry CL et al. Notch inhibition in Kaposi’s sarcoma tumor cells leads to mitotic catastrophe through nuclear factor-kappaB signaling. Mol Cancer Ther. 2007;6(7):1983–92.PubMedCrossRefGoogle Scholar
  45. 45.
    Konishi J et al. Gamma-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers. Cancer Res. 2007;67(17):8051–7.PubMedCrossRefGoogle Scholar
  46. 46.
    Wang H et al. The expression of VEGF and Dll4/Notch pathway molecules in ovarian cancer. Clin Chim Acta. 2014;436C:243–8.CrossRefGoogle Scholar
  47. 47.
    Jundt F et al. Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma. Blood. 2002;99(9):3398–403.PubMedCrossRefGoogle Scholar
  48. 48.
    Sjolund J et al. Suppression of renal cell carcinoma growth by inhibition of Notch signaling in vitro and in vivo. J Clin Invest. 2008;118(1):217–28.PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Ozawa T et al. Nuclear Notch3 expression is associated with tumor recurrence in patients with stage II and III colorectal cancer. Ann Surg Oncol. 2014;21(8):2650–8.PubMedCrossRefGoogle Scholar
  50. 50.
    Dai Y et al. Silencing of Jagged1 inhibits cell growth and invasion in colorectal cancer. Cell Death Dis. 2014;5:e1170.PubMedCrossRefGoogle Scholar
  51. 51.
    Farnie G et al. Novel cell culture technique for primary ductal carcinoma in situ: role of Notch and epidermal growth factor receptor signaling pathways. J Natl Cancer Inst. 2007;99(8):616–27.PubMedCrossRefGoogle Scholar
  52. 52.
    Wong GT et al. Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem. 2004;279(13):12876–82.PubMedCrossRefGoogle Scholar
  53. 53.
    Milano J et al. Modulation of notch processing by gamma-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation. Toxicol Sci. 2004;82(1):341–58.PubMedCrossRefGoogle Scholar
  54. 54.
    Searfoss GH et al. Adipsin, a biomarker of gastrointestinal toxicity mediated by a functional gamma-secretase inhibitor. J Biol Chem. 2003;278(46):46107–16.PubMedCrossRefGoogle Scholar
  55. 55.
    Veenendaal LM et al. Differential Notch and TGFbeta signaling in primary colorectal tumors and their corresponding metastases. Cell Oncol. 2008;30(1):1–11.PubMedGoogle Scholar
  56. 56.
    Rodilla V et al. Jagged1 is the pathological link between Wnt and Notch pathways in colorectal cancer. Proc Natl Acad Sci U S A. 2009;106(15):6315–20.PubMedPubMedCentralCrossRefGoogle Scholar
  57. 57.•
    Espinoza I, Miele L. Notch inhibitors for cancer treatment. Pharmacol Ther. 2013;139(2):95–110. This review article describes the role of Notch signaling and apporoaches inhibit this signaling in various cancers.PubMedPubMedCentralCrossRefGoogle Scholar
  58. 58.
    Hayashi I et al. Neutralization of the gamma-secretase activity by monoclonal antibody against extracellular domain of nicastrin. Oncogene. 2012;31(6):787–98.PubMedPubMedCentralCrossRefGoogle Scholar
  59. 59.
    Funahashi Y et al. A notch1 ectodomain construct inhibits endothelial notch signaling, tumor growth, and angiogenesis. Cancer Res. 2008;68(12):4727–35.PubMedPubMedCentralCrossRefGoogle Scholar
  60. 60.
    Singh A et al. GSI promotes vincristine-induced apoptosis by enhancing multi-polar spindle formation. Cell Cycle. 2014;13(1):157–66.PubMedCrossRefGoogle Scholar
  61. 61.
    Akiyoshi T et al. Gamma-secretase inhibitors enhance taxane-induced mitotic arrest and apoptosis in colon cancer cells. Gastroenterology. 2008;134(1):131–44.PubMedCrossRefGoogle Scholar
  62. 62.••
    Takebe N, Nguyen D, Yang SX. Targeting notch signaling pathway in cancer: clinical development advances and challenges. Pharmacol Ther. 2014;141(2):140–9. This recent review article describes the role of Notch signaling in cancer as well as the agents in use to target Notch signaling in different cancer types.PubMedCrossRefGoogle Scholar
  63. 63.••
    Timme CR, Gruidl M, Yeatman TJ. Gamma-secretase inhibition attenuates oxaliplatin-induced apoptosis through increased Mcl-1 and/or Bcl-xL in human colon cancer cells. Apoptosis. 2013;18(10):1163–74. It is a interesting study where authors have shown gamma-secretase inhibition resulted in decrease in oxaliplatin-induced apoptosis. This study warrants caution while treating colon cancer with the combination of GSIs and chemotherapy.PubMedCrossRefGoogle Scholar
  64. 64.
    Herszenyi L et al. Chemoprevention of colorectal cancer: feasibility in everyday practice? Eur J Cancer Prev. 2008;17(6):502–14.PubMedCrossRefGoogle Scholar
  65. 65.
    Cooper K et al. Chemoprevention of colorectal cancer: systematic review and economic evaluation. Health Technol Assess. 2010;14(32):1–206.Google Scholar
  66. 66.
    Gwyn K, Sinicrope FA. Chemoprevention of colorectal cancer. Am J Gastroenterol. 2002;97(1):13–21.PubMedCrossRefGoogle Scholar
  67. 67.
    Surh YJ. Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer. 2003;3(10):768–80.PubMedCrossRefGoogle Scholar
  68. 68.
    Vadodkar AS et al. Chemoprevention of breast cancer by dietary compounds. Anticancer Agents Med Chem. 2012;12(10):1185–202.PubMedCrossRefGoogle Scholar
  69. 69.
    Mishra LC, Singh BB, Dagenais S. Scientific basis for the therapeutic use of Withania somnifera (Ashwagandha): a review. Altern Med Rev. 2000;5(4):334–46.PubMedGoogle Scholar
  70. 70.
    Malik F et al. A standardized root extract of Withania somnifera and its major constituent withanolide-A elicit humoral and cell-mediated immune responses by up regulation of Th1-dominant polarization in BALB/c mice. Life Sci. 2007;80(16):1525–38.PubMedCrossRefGoogle Scholar
  71. 71.
    Malik F et al. Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic cell death of human myeloid leukemia HL-60 cells by a dietary compound Withaferin A with concomitant protection by N-acetyl cysteine. Apoptosis. 2007;12(11):2115–33.PubMedCrossRefGoogle Scholar
  72. 72.
    Malik F et al. Immune modulation and apoptosis induction: Two sides of antitumoural activity of a standardised herbal formulation of Withania somnifera. Eur J Cancer. 2009;45(8):1494–509.PubMedCrossRefGoogle Scholar
  73. 73.
    Winters M. Ancient medicine, modern use: Withania somnifera and its potential role in integrative oncology. Altern Med Rev. 2006;11(4):269–77.PubMedGoogle Scholar
  74. 74.••
    Vyas AR, Singh SV. Molecular targets and mechanisms of cancer prevention and treatment by withaferin a, a naturally occurring steroidal lactone. AAPS J. 2014;16(1):1–10. The authors have discussed the in vivo potential and molecular targets of WA contributing to its anticancer effects.PubMedPubMedCentralCrossRefGoogle Scholar
  75. 75.
    Mirjalili MH et al. Steroidal lactones from Withania somnifera, an ancient plant for novel medicine. Molecules. 2009;14(7):2373–93.PubMedCrossRefGoogle Scholar
  76. 76.
    Bhattacharya SK, Satyan KS, Ghosal S. Antioxidant activity of glycowithanolides from Withania somnifera. Indian J Exp Biol. 1997;35(3):236–9.PubMedGoogle Scholar
  77. 77.
    Kaileh M et al. Withaferin a strongly elicits IkappaB kinase beta hyperphosphorylation concomitant with potent inhibition of its kinase activity. J Biol Chem. 2007;282(7):4253–64.PubMedCrossRefGoogle Scholar
  78. 78.
    Jayaprakasam B et al. Growth inhibition of human tumor cell lines by withanolides from Withania somnifera leaves. Life Sci. 2003;74(1):125–32.PubMedCrossRefGoogle Scholar
  79. 79.
    Mohan R et al. Withaferin A is a potent inhibitor of angiogenesis. Angiogenesis. 2004;7(2):115–22.PubMedCrossRefGoogle Scholar
  80. 80.
    Bhattacharya SK et al. Effect of Withania somnifera glycowithanolides on a rat model of tardive dyskinesia. Phytomedicine. 2002;9(2):167–70.PubMedCrossRefGoogle Scholar
  81. 81.
    Chowdhury K, Neogy RK. Mode of action of Withaferin A and Withanolide D. Biochem Pharmacol. 1975;24(8):919–20.PubMedCrossRefGoogle Scholar
  82. 82.
    Sabina PE, Chandel S, Raool KM. Evaluation of analgesic, antipyretic and ulcerogenice effect of Withaferin A. Int J Integr Biol. 2009;6(2):52–6.Google Scholar
  83. 83.
    Lahat G et al. Vimentin is a novel anti-cancer therapeutic target; insights from in vitro and in vivo mice xenograft studies. PLoS One. 2010;5(4):e10105.PubMedPubMedCentralCrossRefGoogle Scholar
  84. 84.
    Koduru S et al. Notch-1 inhibition by Withaferin-A: a therapeutic target against colon carcinogenesis. Mol Cancer Ther. 2010;9(1):202–10.PubMedPubMedCentralCrossRefGoogle Scholar
  85. 85.
    Srinivasan S et al. Par-4-dependent apoptosis by the dietary compound Withaferin A in prostate cancer cells. Cancer Res. 2007;67(1):246–53.PubMedCrossRefGoogle Scholar
  86. 86.
    Roy RV et al. Withaferin A, a steroidal lactone from Withania somnifera, induces mitotic catastrophe and growth arrest in prostate cancer cells. J Nat Prod. 2013;76(10):1909–15.PubMedPubMedCentralCrossRefGoogle Scholar
  87. 87.•
    Lee J, Sehrawat A, Singh SV. Withaferin A causes activation of Notch2 and Notch4 in human breast cancer cells. Breast Cancer Res Treat. 2012;136(1):45–56. Authors have shown the effect of WA in breast cancer cells. They showed activation of Notch 2,4 and inactivation of Notch1 by WA. Notch 2 and Notch4 knockdown augmented WA mediated inhibition of cell migration.PubMedPubMedCentralCrossRefGoogle Scholar
  88. 88.•
    Zhang X et al. Inhibition of cell growth and induction of apoptosis in ovarian carcinoma cell lines CaOV3 and SKOV3 by natural withanolide Withaferin A. Gynecol Oncol. 2012;124(3):606–12. Authors have shown WA mediated downregulation of Notch1 and 3 in ovarian cancer cells. This downregulation correlated with induction of apoptosis and cell cycle arrest.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Suman Suman
    • 1
  • Trinath P. Das
    • 1
  • Murali K. Ankem
    • 1
  • Chendil Damodaran
    • 1
    Email author
  1. 1.Department of UrologyUniversity of LouisvilleLouisvilleUSA

Personalised recommendations